Bone marrow samples derived from primary acute leukemia patients (n=8) also showed upregulation of NXF2 mRNA expression following decitabine treatment, and NFX2 was also upregulated in all AML or MDS patients (n=9) treated with decitabine (51). The gene discussed is NXF2; the disease is acute myeloid leukemia.